60 Degrees Pharmaceuticals Inc WT SXTPW

$0.04 0.00 (-0.25%)

Valuation

Market cap: —
Revenue TTM: $250,000
Net income TTM: $-3,770,000
PE ratio: —
Forward PE: —
Profit margin: —
Debt to equity: —

Trading

Volume: 1,600
Avg volume: 5,546
Day's range: $0.04 – $0.04
Shares out: —
Stochastic %K: 58%
Beta: —
Analysts: Sell
Price target: —

Price

Latest news

Oct 1, 2026, 8:03 AM EDT · 2 days ago

60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar

Sep 3, 2026, 8:04 AM EDT · 4 weeks ago

60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference

Aug 14, 2026, 3:47 PM EDT · 7 weeks ago

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

2026-07-30T18:35:43.000Z · 2 months ago

60 Degrees Pharmaceuticals to sell shares and warrants in private placement

Jul 30, 2026, 2:23 PM EDT · 2 months ago

60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules

2026-07-29T21:15:29.000Z · 2 months ago

60 Degrees Pharma babesiosis interim readout planned by October 6

Jul 29, 2026, 4:03 PM EDT · 2 months ago

60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026

Jul 8, 2026, 8:01 AM EDT · 2 months ago

60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases

2026-07-01T12:25:16.000Z · 3 months ago

60 Degrees Pharmaceuticals announces DSMB recommendation for B-Free study

Jul 1, 2026, 8:02 AM EDT · 3 months ago

60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

2026-06-11T13:01:09.000Z · 3 months ago

60 Degrees executes patent licensing agreement with Florida State

Jun 11, 2026, 8:03 AM EDT · 3 months ago

60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement

2026-05-26T14:57:43.000Z · 4 months ago

60 Degrees announces early enrollment of first patient in trial of tafenoquine

May 26, 2026, 8:02 AM EDT · 4 months ago

60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis

2026-05-20T16:00:11.000Z · 4 months ago

H.C. Wainwright downgrades 60 Degrees on ‘untenable’ spending

2026-05-20T15:55:36.000Z · 4 months ago

60 Degrees Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

May 15, 2026, 8:42 AM EDT · 4 months ago

60 Degrees Pharmaceuticals Announces First Quarter 2026 Results

2026-04-15T12:37:07.000Z · 5 months ago

60 Degrees Pharmaceuticals reports Arakoda availability on Runway Health website

Mar 31, 2026, 7:01 AM EDT · 6 months ago

60 Degrees Pharmaceuticals Announces 2025 Annual Results

2026-03-18T12:12:35.000Z · 6 months ago

60 Degrees submits NDIN to FDA for Australian Chestnut Extract

Mar 18, 2026, 8:01 AM EDT · 6 months ago

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

2026-03-11T11:30:55.000Z · 6 months ago

60 Degrees reports all patients cured of babesiosis after tafenoquine treatment

Mar 11, 2026, 7:24 AM EDT · 6 months ago

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

2026-02-02T13:21:06.000Z · 8 months ago

60 Degrees expands access to Arakoda with GoodRx partnership

GDRX

Feb 2, 2026, 8:01 AM EST · 8 months ago

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

2026-01-27T16:30:17.000Z · 8 months ago

60 Degrees Pharmaceuticals target adjusted to $24 at H.C. Wainwright after split

2026-01-22T14:15:44.000Z · 8 months ago

Here’s Why 60 Degrees Pharmaceuticals Stock (SXTP) Rocketed Today

2026-01-22T13:27:13.000Z · 8 months ago

60 Degrees Pharmaceuticals announces partnership with Runway Health

2026-01-17T00:50:18.000Z · 8 months ago

60 Degrees Pharmaceuticals Inc trading halted, news pending

2026-01-15T13:21:52.000Z · 8 months ago

60 Degrees Pharmaceuticals announces approval of 1-for-4 reverse stock split

Jan 15, 2026, 8:01 AM EST · 8 months ago

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

Dec 29, 2025, 8:01 AM EST · 9 months ago

60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State

Dec 11, 2025, 8:01 AM EST · 9 months ago

60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026

Nov 21, 2025, 8:01 AM EST · 10 months ago

60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine

Nov 13, 2025, 1:51 PM EST · 10 months ago

60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

Oct 15, 2025, 7:14 AM EDT · 11 months ago

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

Oct 9, 2025, 7:04 AM EDT · 11 months ago

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

Sep 3, 2025, 8:02 AM EDT · 1 year ago

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

Aug 21, 2025, 8:31 AM EDT · 1 year ago

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 19, 2025, 8:54 AM EDT · 1 year ago

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Aug 13, 2025, 4:14 PM EDT · 1 year ago

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

Jul 16, 2025, 4:01 PM EDT · 1 year ago

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

Jul 15, 2025, 9:10 AM EDT · 1 year ago

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

Jul 15, 2025, 7:01 AM EDT · 1 year ago

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

Jun 4, 2025, 8:56 AM EDT · 1 year ago

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

Jun 3, 2025, 8:49 AM EDT · 1 year ago

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

May 15, 2025, 4:31 PM EDT · 1 year ago

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

Apr 22, 2025, 8:44 AM EDT · 1 year ago

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

Apr 10, 2025, 8:31 AM EDT · 1 year ago

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

Apr 8, 2025, 8:31 AM EDT · 1 year ago

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

Feb 21, 2025, 9:00 AM EST · 1 year ago

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

FTHM

Feb 20, 2025, 10:36 AM EST · 1 year ago

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

Feb 11, 2025, 12:59 PM EST · 1 year ago

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

Feb 6, 2025, 2:07 PM EST · 1 year ago

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 5, 2025, 9:22 AM EST · 1 year ago

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 30, 2025, 2:20 PM EST · 1 year ago

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 28, 2025, 8:01 AM EST · 1 year ago

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Jan 8, 2025, 8:02 AM EST · 1 year ago

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Dec 23, 2024, 8:57 AM EST · 1 year ago

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

Dec 11, 2024, 8:56 AM EST · 1 year ago

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital

Dec 2, 2024, 4:05 PM EST · 1 year ago

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nov 22, 2024, 9:00 AM EST · 1 year ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CANF

Nov 14, 2024, 2:31 PM EST · 1 year ago

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

Oct 3, 2024, 9:02 AM EDT · 2 years ago

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

Sep 4, 2024, 8:00 AM EDT · 2 years ago

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Aug 28, 2024, 2:48 PM EDT · 2 years ago

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements